Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020

Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will announce its third-quarter financial results for the period ended September 30, 2020, on November 10, 2020. The corporate update will be released after market close and made available on their website. Vir focuses on treating serious infectious diseases using innovative immunology technologies. Their development pipeline includes candidates for various diseases such as hepatitis B, influenza A, SARS-CoV-2, HIV, and tuberculosis.

Positive

• Vir's diverse development pipeline targets critical infectious diseases including COVID-19, indicating potential for significant market impact.
• The company is leveraging four technology platforms to enhance immune responses, showcasing innovation in immunology.

Negative

• None.

SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020.

The update will be provided via a press release after market close, and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.  

FAQ

When will Vir Biotechnology report its third-quarter financial results for 2020?

Vir Biotechnology will report its third-quarter financial results on November 10, 2020.

What financial results will Vir Biotechnology announce?

Vir Biotechnology will announce its financial results for the third quarter ended September 30, 2020.

What is Vir Biotechnology's focus in infectious diseases?

Vir Biotechnology focuses on treating and preventing serious infectious diseases utilizing advanced immunology techniques.

Where can I access Vir Biotechnology's press release?

Vir Biotechnology's press release can be accessed on their website under the Investors section.

What diseases are included in Vir Biotechnology's development pipeline?

Vir's development pipeline includes candidates targeting hepatitis B, influenza A, SARS-CoV-2, HIV, and tuberculosis.